1. Home
  2. GSUN vs KPRX Comparison

GSUN vs KPRX Comparison

Compare GSUN & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSUN

Golden Sun Education Group Limited

HOLD

Current Price

$0.33

Market Cap

8.7M

Sector

Real Estate

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.05

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSUN
KPRX
Founded
1997
1998
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7M
8.0M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
GSUN
KPRX
Price
$0.33
$2.05
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
4.1M
22.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$1.76
52 Week High
$3.90
$4.18

Technical Indicators

Market Signals
Indicator
GSUN
KPRX
Relative Strength Index (RSI) 27.49 47.70
Support Level N/A $1.96
Resistance Level $1.39 $2.21
Average True Range (ATR) 0.20 0.09
MACD -0.06 0.01
Stochastic Oscillator 1.37 42.31

Price Performance

Historical Comparison
GSUN
KPRX

About GSUN Golden Sun Education Group Limited

Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: